WEST PHARMACEUTICAL SERVICES INC (WST) Net Income (Loss) Attributable to Parent USD 2010 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
West Pharmaceutical Services Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2010 to 2024.
  • West Pharmaceutical Services Inc Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2024 was $115 M, a 17.6% decline year-over-year.
  • West Pharmaceutical Services Inc Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2024 was $569 M, a 3.01% increase year-over-year.
  • West Pharmaceutical Services Inc annual Net Income (Loss) Attributable to Parent for 2023 was $593 M, a 1.28% increase from 2022.
  • West Pharmaceutical Services Inc annual Net Income (Loss) Attributable to Parent for 2022 was $586 M, a 11.5% decline from 2021.
  • West Pharmaceutical Services Inc annual Net Income (Loss) Attributable to Parent for 2021 was $662 M, a 91.2% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $569 M $115 M -$24.7 M -17.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-04-25
Q4 2023 $593 M $137 M +$34 M +33% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $559 M $161 M +$40.7 M +33.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-10-26
Q2 2023 $519 M $155 M -$33.4 M -17.7% Apr 1, 2023 Jun 30, 2023 10-Q 2023-10-26
Q1 2023 $552 M $140 M -$33.8 M -19.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-25
Q4 2022 $586 M $103 M -$44.7 M -30.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $631 M $121 M -$55 M -31.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-26
Q2 2022 $686 M $189 M +$1.2 M +0.64% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-26
Q1 2022 $684 M $174 M +$22.6 M +14.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-10-26
Q4 2021 $662 M $148 M +$49.3 M +50.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $613 M $176 M +$93.3 M +113% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 $519 M $187 M +$96.1 M +105% Apr 1, 2021 Jun 30, 2021 10-Q 2022-10-27
Q1 2021 $423 M $151 M +$76.9 M +103% Jan 1, 2021 Mar 31, 2021 10-Q 2022-10-27
Q4 2020 $346 M $98.4 M +$34.5 M +54% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-23
Q3 2020 $312 M $82.3 M +$26 M +46.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 $286 M $91.2 M +$25.1 M +38% Apr 1, 2020 Jun 30, 2020 10-Q 2021-10-28
Q1 2020 $261 M $74.3 M +$18.9 M +34.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-10-28
Q4 2019 $242 M $63.9 M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-23
Q3 2019 $56.3 M Jul 1, 2019 Sep 30, 2019 10-K 2021-02-23
Q2 2019 $66.1 M Apr 1, 2019 Jun 30, 2019 10-K 2021-02-23
Q1 2019 $55.4 M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-23
Q1 2012 $29.2 M +$9.6 M +49% Jan 1, 2012 Mar 31, 2012 10-Q 2012-05-04
Q3 2011 $16.9 M -$900 K -5.06% Jul 1, 2011 Sep 30, 2011 10-Q 2011-11-07
Q2 2011 $20.1 M -$1.6 M -7.37% Apr 1, 2011 Jun 30, 2011 10-Q/A 2011-08-08
Q1 2011 $19.6 M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-04
Q3 2010 $17.8 M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-07
Q2 2010 $21.7 M Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.